The Serono Maia Clone prostatic-specific antigen (PSA) kit incorporates an immunoradiometric assay for the measurement of PSA in the serum. The method can be used over a range of 0-100 ng/ml without dilution. Standard concentrations are 0. 0.4, 1. 5, 20, and 100 ng/ml. Up to date, 373 normal men, 89 normal women, 117 prostatic carcinoma, 98 other carcinoma, and 85 benign prostatic hypertrophy have been tested. The aim of this study is to evaluate the sensitivity and specificity of a new immunoassay method for the determination of PSA, that could be able to evaluate low levels of PSA, resulted undetectable with other methods. This ability could be useful in patients treated with hormone-suppressive therapy or after radical prostatectomy. We have collected all low values present in samples examined. With the Serono Maia Clone PSA kit only 26.7% of these have been evaluated as 'out' values as opposed to 46.5% with the Hybritech kit.
NEW ULTRASENSITIVE ASSAY DEVELOPMENT BY USING MONOCLONAL-ANTIBODIES FOR DETECTING PROSTATE-SPECIFIC ANTIGEN / DI SILVERIO, Franco; D'Eramo, Giuseppe; G. P., Flammia; M., Caponera; D., Macri; A., Loreto; Sciarra, Alessandro. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - STAMPA. - 21:1(1992), pp. 79-82. (Intervento presentato al convegno 2ND MEDITERRANEAN CONGRESS OF UROLOGY : MARKERS IN UROLOGY tenutosi a ROME, ITALY nel JUL 03-06, 1991).
NEW ULTRASENSITIVE ASSAY DEVELOPMENT BY USING MONOCLONAL-ANTIBODIES FOR DETECTING PROSTATE-SPECIFIC ANTIGEN
DI SILVERIO, Franco;D'ERAMO, Giuseppe;SCIARRA, Alessandro
1992
Abstract
The Serono Maia Clone prostatic-specific antigen (PSA) kit incorporates an immunoradiometric assay for the measurement of PSA in the serum. The method can be used over a range of 0-100 ng/ml without dilution. Standard concentrations are 0. 0.4, 1. 5, 20, and 100 ng/ml. Up to date, 373 normal men, 89 normal women, 117 prostatic carcinoma, 98 other carcinoma, and 85 benign prostatic hypertrophy have been tested. The aim of this study is to evaluate the sensitivity and specificity of a new immunoassay method for the determination of PSA, that could be able to evaluate low levels of PSA, resulted undetectable with other methods. This ability could be useful in patients treated with hormone-suppressive therapy or after radical prostatectomy. We have collected all low values present in samples examined. With the Serono Maia Clone PSA kit only 26.7% of these have been evaluated as 'out' values as opposed to 46.5% with the Hybritech kit.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.